×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
GILD – gilead sciences, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
GILD
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/23
04:25 pm
gild
Gilead Sciences to Present at Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Gilead Sciences to Present at Upcoming Investor Conferences [Yahoo! Finance]
2/23
04:05 pm
gild
Gilead Sciences to Present at Upcoming Investor Conferences
Low
Report
Gilead Sciences to Present at Upcoming Investor Conferences
2/23
11:23 am
gild
Gilead Sciences (NASDAQ:GILD) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $170.00 price target on the stock.
Low
Report
Gilead Sciences (NASDAQ:GILD) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $170.00 price target on the stock.
2/23
09:23 am
gild
Gilead Sciences to Acquire Arcellx in $7.8 Billion Deal [Yahoo! Finance]
Low
Report
Gilead Sciences to Acquire Arcellx in $7.8 Billion Deal [Yahoo! Finance]
2/23
08:07 am
gild
Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion [Yahoo! Finance Canada]
Low
Report
Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion [Yahoo! Finance Canada]
2/23
06:46 am
gild
M&A Snapshot: Gilead acquires Arcellx for $7.8B [Seeking Alpha]
Low
Report
M&A Snapshot: Gilead acquires Arcellx for $7.8B [Seeking Alpha]
2/23
06:41 am
gild
Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion [CNBC]
Low
Report
Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion [CNBC]
2/23
06:10 am
gild
Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel [Yahoo! Finance]
Low
Report
Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/23
06:46 am
gild
Form 8-K GILEAD SCIENCES, INC. For: Feb 22
Low
Report
Form 8-K GILEAD SCIENCES, INC. For: Feb 22
2/18
05:23 pm
gild
Form 4 GILEAD SCIENCES, INC. For: Feb 17 Filed by: Mercier Johanna
Low
Report
Form 4 GILEAD SCIENCES, INC. For: Feb 17 Filed by: Mercier Johanna
2/18
05:12 pm
gild
Form 4 GILEAD SCIENCES, INC. For: Feb 17 Filed by: Dickinson Andrew D
Low
Report
Form 4 GILEAD SCIENCES, INC. For: Feb 17 Filed by: Dickinson Andrew D
2/17
04:09 pm
gild
Form 144 GILEAD SCIENCES, INC. Filed by: Mercier Johanna
Low
Report
Form 144 GILEAD SCIENCES, INC. Filed by: Mercier Johanna
2/17
04:07 pm
gild
Form 144 GILEAD SCIENCES, INC. Filed by: Dickinson Andrew D
Low
Report
Form 144 GILEAD SCIENCES, INC. Filed by: Dickinson Andrew D
2/12
07:27 pm
gild
Form 3 GILEAD SCIENCES, INC. For: Feb 04 Filed by: Cain Wettan Keeley M
Low
Report
Form 3 GILEAD SCIENCES, INC. For: Feb 04 Filed by: Cain Wettan Keeley M
2/12
04:37 pm
gild
Form 13F-HR GILEAD SCIENCES, INC. For: Dec 31
Low
Report
Form 13F-HR GILEAD SCIENCES, INC. For: Dec 31
2/10
04:02 pm
gild
Form 8-K GILEAD SCIENCES, INC. For: Feb 10
High
Report
Form 8-K GILEAD SCIENCES, INC. For: Feb 10
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/18
Japanese flu drug appears ‘effective’ in coronavirus treatment in Chinese clinical trials [TechCrunch Blog]
9.5%
3/1 2 Stocks That Can Help You Protect Your Wealth From a Coronavirus Pandemic [The Motley Fool] 8.3%
2/25 U.S. Health Officials Start First Clinical Trial With Gilead Sciences' Experimental Coronavirus Treatment [The Motley Fool] 6.6%
3/6 Can Gilead Change Its Dim Fortunes On An Immuno-Oncology Buyout? [Investor's Business Daily] 6.4%
4/2 Gilead in-licenses multiple CAR antibodies from TeneoBio [Seeking Alpha] 6.2%
4/29 Gilead's remdesivir meets main goal of trial in COVID-19 patients [Reuters] 5.5%
1/31 UPDATE 2-Gilead working with China to test Ebola drug as new coronavirus treatment [Reuters] 5.0%
3/10 Gilead Presents 96-week DISCOVER Trial Data Demonstrating Favorable Renal and Bone Safety Profile of Descovy® for HIV PrEP in At-Risk Populations 4.7%
3/26 Gilead Sciences, Inc. (NASDAQ: GILD) had its "buy" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $83.00 price target on the stock. 4.5%
4/24 European shares slide as EU stimulus fails to impress [Reuters] 3.8%
3/1 2 Stocks That Can Help You Protect Your Wealth From a Coronavirus Pandemic [The Motley Fool] 8.3%
2/25 U.S. Health Officials Start First Clinical Trial With Gilead Sciences' Experimental Coronavirus Treatment [The Motley Fool] 6.6%
3/6 Can Gilead Change Its Dim Fortunes On An Immuno-Oncology Buyout? [Investor's Business Daily] 6.4%
4/2 Gilead in-licenses multiple CAR antibodies from TeneoBio [Seeking Alpha] 6.2%
4/29 Gilead's remdesivir meets main goal of trial in COVID-19 patients [Reuters] 5.5%
1/31 UPDATE 2-Gilead working with China to test Ebola drug as new coronavirus treatment [Reuters] 5.0%
3/10 Gilead Presents 96-week DISCOVER Trial Data Demonstrating Favorable Renal and Bone Safety Profile of Descovy® for HIV PrEP in At-Risk Populations 4.7%
3/26 Gilead Sciences, Inc. (NASDAQ: GILD) had its "buy" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $83.00 price target on the stock. 4.5%
4/24 European shares slide as EU stimulus fails to impress [Reuters] 3.8%
TOP News Decliners
3/20
Gilead Sciences, Inc. (NASDAQ: GILD) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $90.00 price target on the stock, up previously from $70.00.
-9.3%
2/27 Gilead Sciences, Inc. (NASDAQ: GILD) is now covered by analysts at Barclays PLC. They set an "underweight" rating on the stock. -9.1%
3/6 Gilead Surges To 2-Year High On Expectations For Speedy Coronavirus Drug [Investor's Business Daily] -8.4%
2/3 Gilead +12% on coronavirus treatment testing [Seeking Alpha] -7.3%
3/11 The index dropped at least 20% from its recent peak as coronavirus continues to whiplash investors [CNN] -6.6%
2/25 U.S. Stock-Index Futures Advance on Dip-Buying After Rout [Yahoo! Finance News] -6.4%
2/27 Gilead Sciences makes takeover approach to Forty Seven: Bloomberg News [Reuters] -6.3%
4/16 Gilead surges after report suggests COVID-19 patients responding to remdesivir [Reuters] -5.8%
3/24 Form DEF 14A GILEAD SCIENCES INC For: May 06 -5.6%
4/20 Dow futures fall more than 150 points as US crude prices plunge [CNBC] -5.0%
2/27 Gilead Sciences, Inc. (NASDAQ: GILD) is now covered by analysts at Barclays PLC. They set an "underweight" rating on the stock. -9.1%
3/6 Gilead Surges To 2-Year High On Expectations For Speedy Coronavirus Drug [Investor's Business Daily] -8.4%
2/3 Gilead +12% on coronavirus treatment testing [Seeking Alpha] -7.3%
3/11 The index dropped at least 20% from its recent peak as coronavirus continues to whiplash investors [CNN] -6.6%
2/25 U.S. Stock-Index Futures Advance on Dip-Buying After Rout [Yahoo! Finance News] -6.4%
2/27 Gilead Sciences makes takeover approach to Forty Seven: Bloomberg News [Reuters] -6.3%
4/16 Gilead surges after report suggests COVID-19 patients responding to remdesivir [Reuters] -5.8%
3/24 Form DEF 14A GILEAD SCIENCES INC For: May 06 -5.6%
4/20 Dow futures fall more than 150 points as US crude prices plunge [CNBC] -5.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: